Bruce Booth sold $22M of KYMR
director at Kymera Therapeutics, Inc.. 236,588 shares at an average of $91.72, traded Dec 10, 2025, filed Dec 12, 2025.
Score components
- +15RoleDirector
- +25Trade size$21.7M at market
- 0Share of holdings soldSold 5.7% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-25-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -31,459 | $88.64 | $2.8M | 4,141,757 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -17,825 | $89.25 | $1.6M | 4,123,932 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -10,545 | $90.14 | $951k | 4,113,387 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -47,349 | $92.41 | $4.4M | 4,066,038 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -85,862 | $93.20 | $8.0M | 3,980,176 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -5,979 | $88.64 | $530k | 717,267 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -3,391 | $89.25 | $303k | 713,876 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -2,001 | $90.14 | $180k | 711,875 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -9,060 | $92.41 | $837k | 702,815 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stockindirect: See footnote | -16,338 | $93.20 | $1.5M | 686,477 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stockindirect: See footnote | -5,125 | $91.23 | $468k | 3,975,051 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stockindirect: See footnote | -976 | $91.23 | $89k | 685,501 | Dec 12, 2025 |
| Dec 12, 2025 | SOpen-market sale Common Stockindirect: See footnote | -570 | $91.04 | $52k | 3,974,481 | Dec 12, 2025 |
| Dec 12, 2025 | SOpen-market sale Common Stockindirect: See footnote | -108 | $91.04 | $9,832 | 685,393 | Dec 12, 2025 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 40Moderate | Kymera Therapeutics, Inc. | Pamela Esposito director | $2.3M 27,563 shares | -100% | |
| 50Moderate | KYMRbuy Kymera Therapeutics, Inc. | Baker Bros. Advisors LP director, owner | $172M 2,005,813 shares | +376% | |
| 32Weak | Kymera Therapeutics, Inc. | Jeffrey W. Albers director | $449k 5,000 shares | -100% | |
| 30Weak | Kymera Therapeutics, Inc. | Jared Gollob Chief Medical Officer | $4.4M 49,307 shares | -31% | |
| 23Weak | Kymera Therapeutics, Inc. | Jared Gollob Chief Medical Officer | $3.7M 59,576 shares | -35% | |
| 22Weak | Kymera Therapeutics, Inc. | Jeffrey W. Albers director | $296k 5,000 shares | -100% | |
| 0Weak | Kymera Therapeutics, Inc. | Jared Gollob Chief Medical Officer | $187k 3,114 shares | -3% | |
| 30Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $4.0M 79,220 shares | -26% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.